

Biodistribution of AAVpo1 and AAVpo1A1 in mice with myotubular myopathy

Edith Renaud-Gabardos, Paloma Navas-Navarro, Jihad Elandari, Louise Mangin, Karine Poulard, Samia Martin, Dirk Grimm, Ana Buj-Bello

▶ To cite this version:

Edith Renaud-Gabardos, Paloma Navas-Navarro, Jihad Elandari, Louise Mangin, Karine Poulard, et al.. Biodistribution of AAVpo1 and AAVpo1A1 in mice with myotubular myopathy. ASGCT 2020, May 2020, Boston (MA), United States. hal-04442079

HAL Id: hal-04442079

https://hal.science/hal-04442079

Submitted on 6 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Biodistribution of AAVpo1 and AAVpo1A1 in mice with myotubular myopathy



Tissue harvesting

and analysis



Edith Renaud-Gabardos^{1,2}, Paloma Navas-Navarro^{1,2}, Jonas Weinmann³, Jihad Elandari³, Louise Mangin^{1,2}, Karine Poulard^{1,2}, Samia Martin², Dirk Grimm³, Ana Buj Bello^{1,2}

UniversitätsKlinikum H

Genethon, UMR_S951 Inserm, Univ Evry, Université Paris Saclay, Evry, France. Genethon, Evry, France. Department of Infectious Diseases and Virology, BioQuant BQ0030, Heidelberg University, Germany.

INTRODUCTION:


Recombinant adeno-associated viral (AAV) vectors are powerful vehicles for *in vivo* delivery of therapeutic transgenes. Tissue tropism and consequently vector dosage for gene therapy can vary amongst naturally occurring and engineered AAV serotypes. We previously reported that serotype 8 AAV-mediated MTM1 gene delivery can correct the phenotype of murine and canine models of myotubular myopathy, a severe pediatric disorder leading to generalized muscle weakness and respiratory failure in patients.


In order to identify AAV vectors with increased skeletal muscle potency in myotubularin deficient muscle, in the present study we compared the biodistribution and transgene expression of serotype 8, 9 and rh10 vectors with AAVpo1, and its derivative AAVpo1A1, of porcine origin that carry a MTM1 expression cassette.

METHODS: AAV8 AAV9 AAVrh10 AAVpo1 AAVpo1A1 Desmin promoter miRNA208a Mtm1 KO mice 3 weeks 7 weeks

RESULTS:

Intravenous administration of AAVpo1- and AAVpo1A1-MTM1 vectors resulted in higher body and muscle weight in myotubularin-deficient mice compared to AAV8-MTM1







IV Injection


2^e13 VG/Kg


The AAVpo1A1 vector transduced muscles as efficiently as the AAV8 vector but detargeted main organs, including liver





AAVpo1A1-MTM1 administration resulted in higher transgene expression in skeletal muscles compared to AAV8, reaching levels





CONCLUSIONS:

We found that administration of AAV9-, AAVrh10- and AAVpo1A1 vectors in Mtm1-KO mice resulted in higher myotubularin expression levels in skeletal muscles compared to AAV8- and AAVpo1 vectors. In addition, the AAVpo1A1 capsid detargeted liver transduction. These results indicate that AAVpo1A1 vectors may be suitable for gene transfer in myotubular myopathy, and other myopathies.





